IN-HOME Study
Research type
Research Study
Full title
Home Monitoring of Creatinine in Cancer Patients: Assessing Acceptability and Clinical Benefit
IRAS ID
255751
Contact name
Sandip Mitra
Contact email
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Patients with reduced kidney function probably have a higher risk of cancer, the reasons for which are not fully clear. When people with reduced kidney function do get cancer, some research suggests that their outcomes are worse, but again the reasons for this aren’t clear.
When new cancer drugs are tested in clinical trials, it is usually on people with good kidney function because there is concern over damaging patients’ kidneys with the drugs. This could lead patients with reduced kidney function having fewer options for treatment when they do get cancer because over a perceived risk of causing more damage to their kidneys.
One way of potentially mitigating the risk of damaging people kidneys with cancer treatments is by improving the monitoring of their kidney function so that this may lead to earlier detection of something going wrong with the kidneys.
This study will explore intensive, home based monitoring of creatinine in patients receiving treatment for cancer to see if patients are accepting of this form of intensive monitoring and also if it leads to earlier detection of problems with the kidneys.REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
19/NW/0164
Date of REC Opinion
9 May 2019
REC opinion
Further Information Favourable Opinion